SCHEMBL4074777

SCHEMBL4074777

CCCCCc1ccnc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.53
LOX P28300 1/20 0.53
LOXL3 P58215 1/20 0.53
LOXL2 Q9Y4K0 1/20 0.53
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PTGS2 P35354 3/20 0.41
CYP3A4 P08684 2/20 0.41
LPL P06858 2/20 0.41
LIPG Q9Y5X9 2/20 0.41
LNPEP Q9UIQ6 1/20 0.40
ESR1 P03372 2/20 0.40
ADRA2A P08913 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
TACR2 P21452 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27672336 0.98 RECQL (0.52) RECQLLOXLOXL3LOXL2TDP1
SCHEMBL27878725 0.98 RECQL (0.52) RECQLLOXLOXL3LOXL2TDP1
SCHEMBL27902689 0.98 RECQL (0.52) RECQLLOXLOXL3LOXL2TDP1
SCHEMBL4438687 0.86 RECQL (0.59) RECQLLOXLOXL3LOXL2CYP3A4
SCHEMBL7455147 0.82 RECQL (0.59) RECQLLOXLOXL3LOXL2TDP1
SCHEMBL1328611 0.81 LNPEP (0.48) TDP1L3MBTL1PTGS2CYP3A4LPL
Hydrochloric Acid SCHEMBL28861654 0.80 LOX (0.61) RECQLLOXLOXL3LOXL2GSK3A
SCHEMBL24668667 0.79 RECQL (0.55) RECQLLOXLOXL3LOXL2TDP1
SCHEMBL11798255 0.79 TDP1 (0.46) TDP1L3MBTL1PTGS2CYP3A4LPL
SCHEMBL16544526 0.79 CYP3A4 (0.50) TDP1L3MBTL1PTGS2CYP3A4LPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115558196-A Self-repairing anti-impact PP special material and preparation method thereof 万华化学集团股份有限公司 2023-01-03 CN disclosed
CN-104600352-B Sodium rechargeable battery with the graphite felt for forming air vent channel SK INNOVATION CO.,LTD. (KR) 2019-11-01 CN disclosed
CN-106457909-B Tire 株式会社普利司通 2018-12-07 CN disclosed
CN-104300153-B Include the sodium rechargeable battery of graphite felt SK新技术株式会社 2018-09-07 CN disclosed
CN-104078686-B Current-collector for secondary cell and the secondary cell comprising it SK新技术株式会社 2017-12-22 CN disclosed
CN-105188913-B Method for regenerant ions compound 信实工业公司 2017-09-19 CN disclosed
CN-106457909-A Tire 株式会社普利司通 2017-02-22 CN disclosed
CN-102498122-B Biomass by hydrolyzation 威斯康星校友研究基金会 2016-08-03 CN disclosed
CN-105188913-A A process for regenerating ionic compound RELIANCE IND LTD 2015-12-23 CN disclosed
CN-102666665-B Silicone compositions comprising a swollen silicone gel DOW CORNING 2015-07-22 CN disclosed
US-20090315454-A1 IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE SHOWA DENKO K.K. (JP) 2009-12-24 US disclosed
CN-101535325-A Iridium complex compound, organic electroluminescent device obtained using the same, and use of the device SHOWA DENKO KK (JP) 2009-09-16 CN disclosed
EP-2084171-A1 IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE Showa Denko K.K. (JP) 2009-08-05 EP disclosed
WO-2008056799-A1 IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE SHOWA DENKO K.K. (JP) 2008-05-15 WO disclosed
WO-2008056799-A1 IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE SHOWA DENKO K.K. (JP) 2008-05-15 WO disclosed
EP-1572693-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS Pharmacia Corporation (US) 2005-09-14 EP disclosed
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds PHARMACIA CORPORATION 2004-10-21 US disclosed
WO-2004058762-A1 MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS PHARMACIA CORPORATION (US) 2004-07-15 WO disclosed
EP-1218360-A1 TRIAZINE KINASE INHIBITORS Amgen Inc., (US) 2002-07-03 EP disclosed
WO-2001025220-A1 TRIAZINE KINASE INHIBITORS AMGEN INC. (US) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090315454-A1 IRIDIUM COMPLEX COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE OBTAINED BY USING THE SAME, AND USES OF THE DEVICE ELP1, RUVBL1, LIG1 RECQL 483/4885LOX 3021/4885LOXL3 1414/4885
US-20040209897-A1 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds MAPKAPK2, MAP3K2, MKNK2 RECQL 3340/4885LOX 1332/4885LOXL3 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.